CG Oncology’s (CGON) Buy Rating Reiterated at HC Wainwright

CG Oncology (NASDAQ:CGON)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $75.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 162.88% from the company’s previous close.

CGON has been the topic of a number of other research reports. Morgan Stanley reaffirmed an “overweight” rating and issued a $55.00 price objective on shares of CG Oncology in a research report on Friday, March 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $66.00 price objective on shares of CG Oncology in a research report on Friday, December 6th. Finally, TD Cowen began coverage on CG Oncology in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, CG Oncology currently has a consensus rating of “Buy” and a consensus target price of $63.88.

CG Oncology Price Performance

CGON opened at $28.53 on Tuesday. CG Oncology has a 12 month low of $23.91 and a 12 month high of $46.99. The stock has a fifty day moving average price of $28.08 and a 200-day moving average price of $32.09.

Insider Transactions at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of CG Oncology during the 4th quarter worth approximately $41,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in CG Oncology during the fourth quarter worth $68,000. KLP Kapitalforvaltning AS acquired a new stake in CG Oncology during the fourth quarter valued at $100,000. Federated Hermes Inc. purchased a new position in CG Oncology in the fourth quarter valued at $172,000. Finally, Meeder Asset Management Inc. acquired a new position in shares of CG Oncology in the fourth quarter worth about $189,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.